In contrast, targeting DUSP5 and −6 phosphatase activity with inhibitor (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI) affected the growth of both FLT3-ITD+ AML and healthy PBCSs, albeit with different efficiency, as shown by inhibitor experiments (Figure S4D), suggesting that there may be a therapeutic window. Here, DUSP5 is linked to acute myeloid leukemia.